Phase III study of Efficacy and Safety of SJP-0118 in bacterial blepharitis, dacryocystitis or hordeolum/ acute suppurative chalazion.
Phase of Trial: Phase III
Latest Information Update: 29 Jul 2016
At a glance
- Drugs SJP 0118 (Primary)
- Indications Blepharitis; Chalazion; Dacryocystitis
- Focus Therapeutic Use
- Sponsors Senju Pharmaceutical
- 28 Jul 2016 Status changed from recruiting to completed.
- 13 Nov 2015 New trial record